Physical activity and incidence of sarcopenia: the population-based AGES-Reykavik Study
Physical activity and incidence of sarcopenia: the population-based AGES-Reykavik Study
复制标题
DOI：
10.1093/ageing/afw090
复制
发表时间：
2016-09-01
期刊：
影响因子：
6.7
通讯作者：
Harris, Tamara
中科院分区：
文献类型：
--
作者：
Mijinarends, Donja M.;Koster, Annemarie;Harris, Tamara
背景：肌肉减少症的患病率随着年龄的增长而增加。体育活动可能会减缓肌肉流失的速度，从而降低肌肉减少症的发病率。目的：研究5年内体育锻炼与肌肉减少症的关系。设计：数据来自基于人群的年龄、基因/环境、易感性-雷克雅未克研究。设置：研究开始时居住在雷克雅未克地区的人。研究对象：研究对象为年龄在66-93岁之间的2309人。方法：采用自述问卷法对中高强度体力活动（MVPA）进行评估。使用欧洲老年人肌肉减少症工作组算法确定肌肉减少症，包括肌肉质量（计算机断层扫描成像），握力（计算机测力计）和步态速度（6米）。结果：参与者的平均年龄为74.9±4.7岁。基线时肌肉减少症患病率为7.3%，随访时为16.8%。运动最少者5年骨骼肌减少症发生率为14.8%，运动最多者为9.0%。与最不活跃的参与者相比，报告MVPA中高量的参与者发生肌肉减少症的可能性显著降低（OR = 0.64, 95% CI 0.45-0.91）。MVPA水平高的参与者肌肉质量、力量和步行速度的基线水平更高，但基线MVPA与肌肉损失率无关。结论：高剂量的MVPA似乎有助于对抗肌肉减少症的发展。为了延缓肌肉减少症的发病及其潜在的不良后果，应注意增加老年人的身体活动水平。
Background: the prevalence of sarcopenia increases with age. Physical activity might slow the rate of muscle loss and therewith the incidence of sarcopenia.Objective: to examine the association of physical activity with incident sarcopenia over a 5-year period.Design: data from the population-based Age, Gene/Environment, Susceptibility-Reykjavik Study were used.Setting: people residing in the Reykjavik area at the start of the study.Subjects: the study included people aged 66-93 years (n = 2309).Methods: the amount of moderate-vigorous physical activity (MVPA) was assessed by a self-reported questionnaire. Sarcopenia was identified using the European Working Group on Sarcopenia in Older People algorithm, including muscle mass (computed tomography imaging), grip strength (computerised dynamometer) and gait speed (6 m).Results: mean age of the participants was 74.9 +/- 4.7 years. The prevalence of sarcopenia was 7.3% at baseline and 16.8% at follow-up. The incidence proportion of sarcopenia over 5 years was 14.8% in the least-active individuals and 9.0% in the most-active individuals. Compared with the least-active participants, those reporting a moderate-high amount of MVPA had a significantly lower likelihood of incident sarcopenia (OR = 0.64, 95% CI 0.45-0.91). Participants with a high amount of MVPA had higher baseline levels of muscle mass, strength and walking speed, but baseline MVPA was not associated with the rate of muscle loss.Conclusion: a higher amount of MVPA seems to contribute to counteracting the development of sarcopenia. To delay the onset of sarcopenia and its potential adverse outcomes, attention should be paid to increasing physical activity levels in older adults.